{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:16:14Z","timestamp":1793322974724,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bcmd.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:44:15Z","timestamp":1445553855000},"page":"140-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24 months"],"prefix":"10.1016","volume":"59","author":[{"given":"Hiroyuki","family":"Ida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruaki","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3063-6435","authenticated-orcid":false,"given":"Hak-Myung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Mellgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.10.002_bb0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation.V2012.1.13.3797921","article-title":"Gaucher disease and other storage disorders","volume":"2012","author":"Grabowski","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bcmd.2015.10.002_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1005313724361","article-title":"Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations","volume":"20","author":"Ida","year":"1997","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/bcmd.1998.0172","article-title":"Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients","volume":"24","author":"Ida","year":"1998","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0020","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymgme.2009.05.001","article-title":"Clinical and genetic study of Japanese patients with type 3 Gaucher disease","volume":"97","author":"Tajima","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0025","first-page":"131","article-title":"Examination of the efficacy and safety of enzyme replacement therapy with velaglucerase alfa in Japanese Gaucher disease patients","volume":"78","author":"Ida","year":"2015","journal-title":"J. Pediatr. Pract."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0040","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.10.002_bb0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/gim.2013.154","article-title":"A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability","volume":"16","author":"Pastores","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0065","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","volume":"90","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","article-title":"Seven-year safety and efficacy with velaglucerase alfa for treatment-na\u00efve adult patients with type 1 Gaucher disease","volume":"90","author":"Zimran","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0075","article-title":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase","author":"Smith","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0080","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.bcmd.2015.10.002_bb0085","series-title":"Radiographic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1959"},{"key":"10.1016\/j.bcmd.2015.10.002_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ibd.22979","article-title":"Determination of bone age in pediatric patients with Crohn's disease should become part of routine care","volume":"19","author":"Gupta","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0095","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","article-title":"Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score","volume":"188","author":"Robertson","year":"2007","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10545-010-9095-5","article-title":"The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG)","volume":"33","author":"Cherin","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0105","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archopht.122.9.1395","article-title":"Vitreous opacities and retinal vascular abnormalities in Gaucher disease","volume":"122","author":"Shrier","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.10.002_bb0115","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0120","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.2214\/AJR.14.13563","article-title":"Quantification of bone marrow involvement in treated Gaucher disease with proton MR spectroscopy: correlation with bone marrow MRI scores and clinical status","volume":"204","author":"Jaramillo","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","article-title":"Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease","volume":"37","author":"Maas","year":"2008","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.bcmd.2015.10.002_bb0130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615300024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615300024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:32:40Z","timestamp":1761049960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615300024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":26,"alternative-id":["S1079979615300024"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.10.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors and Shire. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}